文献速递病毒性肝炎

未治疗与治疗中慢性乙型肝炎肝硬化风险评分模型的开发与验证

Development and Validation of a Risk Score for Liver Cirrhosis Prediction in Untreated and Treated Chronic Hepatitis B.
PubMed 文献 · J Infect Dis · 2021-01-01

基于美国6中心3000例慢性乙型肝炎患者(52.60%接受抗病毒治疗)开发13分肝硬化风险评分,并在台湾4552例(21.27%接受治疗)中外部验证。预测3、5、10年肝硬化的AUROC在开发队列为0.82、0.85、0.89,验证队列为0.82、0.79、0.77。该简易模型适用于未治疗和治疗中的慢性乙型肝炎患者。

要点

  • 性别、年龄、糖尿病、抗病毒治疗状态/时长、HBeAg及基线ALT/AST是肝硬化独立预测因子。
  • 13分风险评分在开发队列预测3、5、10年肝硬化AUROC为0.82、0.85、0.89。
  • 外部验证队列对应AUROC为0.82、0.79、0.77,适用于不同地区与治疗状态患者。

核心结论

  • 开发并外部验证了一个简易肝硬化风险评分模型,可用于未治疗和治疗中的慢性乙型肝炎患者。

研究设计与样本

  • 开发队列纳入美国6中心3000例慢性乙型肝炎患者,52.60%接受抗病毒治疗。
  • 外部验证纳入台湾类似队列4552例慢性乙型肝炎个体,21.27%接受治疗。
  • 采用Cox比例风险回归筛选预测因子并建立风险评分,计算AUROC评估预测价值。

主要发现

  • 性别、年龄、糖尿病、抗病毒治疗状态/时长、HBeAg及基线ALT/AST水平与肝硬化风险升高显著相关。
  • 基于上述预测因子建立13分风险评分。
  • 开发队列预测3、5、10年肝硬化风险的AUROC分别为0.82、0.85、0.89。
  • 验证队列预测3、5、10年肝硬化风险的AUROC分别为0.82、0.79、0.77。

关键数值与推荐

  • 风险评分总分为13分,基于性别、年龄、糖尿病、抗病毒治疗状态/时长、HBeAg及基线ALT/AST。
  • 开发队列3、5、10年肝硬化预测AUROC分别为0.82、0.85、0.89。
  • 验证队列3、5、10年肝硬化预测AUROC分别为0.82、0.79、0.77。

临床怎么用

  • 该评分可用于未治疗和治疗中的慢性乙型肝炎患者,辅助评估肝硬化风险。
  • 模型在不同地区(美国与台湾)和不同治疗状态人群中得到验证,具有较好适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic hepatitis B (CHB) can progress to cirrhosis, but there are limited noninvasive tools available to estimate cirrhosis risk, including in patients receiving antiviral therapy. This study developed and validated a simple model to assess risk in CHB patients. METHODS: The derivation cohort included 3000 CHB patients from 6 centers in the United States, with 52.60% receiving antiviral therapy. External validation was performed for 4552 CHB individuals from similar cohorts in Taiwan, with 21.27% receiving therapy. Cox proportional hazards regression analyses were used to screen predictors and develop the risk score for cirrhosis. Areas under receiver operating characteristic curves (AUROCs) were calculated for predictive value. RESULTS: Sex, age, diabetes, antiviral treatment status/duration, hepatitis B e-antigen, and baseline alanine aminotransferase/aspartate aminotransferase levels were significantly associated with increased cirrhosis risk. A 13-point risk score was developed based on these predictors. The AUROCs for predicting cirrhosis risk were 0.82 at 3 years, 0.85 at 5 years, and 0.89 at 10 years in the derivation cohort, and 0.82, 0.79, and 0.77 in the validation cohort, respectively. CONCLUSIONS: We developed and validated a simple cirrhosis prediction model with an independent external cohort that can be applied to both treatment-naive and treatment-experienced CHB patients in diverse settings and locations.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Le AK, Yang HI, Yeh ML, et al. Development and Validation of a Risk Score for Liver Cirrhosis Prediction in Untreated and Treated Chronic Hepatitis B. J Infect Dis. 2021. PMID: 32525978. doi:10.1093/infdis/jiaa330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。